Literature DB >> 20471897

Cardiovascular risk induced by low-dose corticosteroids in rheumatoid arthritis: a systematic literature review.

Adeline Ruyssen-Witrand1, Bruno Fautrel, Alain Saraux, Xavier Le Loët, Thao Pham.   

Abstract

OBJECTIVES: To assess the association between cardiovascular (CV) risk and low-dose corticosteroids (LD-CT, defined as a daily dose <10mg/day of prednisone) in rheumatoid arthritis (RA) patients. DATA SOURCE: A systematic review of the literature up to June 2009 was performed. DATA EXTRACTION: (1) cardiovascular risk factors: high blood pressure, glycemia and lipid profile, carotid intima-media thickness, pulse-wave velocity, ventricular function; (2) "hard" outcomes: heart failure (HF), stroke, myocardial infarction (MI) or mortality. DATA ANALYSIS: descriptive, comparing CV risk between LD-CT-treated RA patients and LD-CT-non-treated RA patients.
RESULTS: Of the 1138 screened reports, the literature search identified 37 assessing CV risk in LD-CT treated RA. The analysis showed a protective effect on serum lipid profile, an increase of insulin resistance or glycemia, probably no effect on blood pressure, no effect on atherosclerosis, discrepancies regarding arterial stiffness and no effect on ventricular function or heart rate variability. An association of LD-CT with major CV events was found in 4/6 studies. This included MI (HR=1.7 [1.2-2.3]), stroke (OR=4.36 [1.60-11.90] for LDC between 6 and 10mg/day), mortality (HR=2.03 [1.25-3.32]) and a composite index of CV events (in the group of rheumatoid factor positive RA, HR=2.21 [1.22-4.00]). Two studies did not find any significant association between LD-CT exposure and mortality (OR=2.25 [0.29-102.5]) or a composite index of CV events (OR=1.3 [0.8-2.0]).
CONCLUSION: Although the literature review showed poor association between LDC exposure and CV risk factors, a trend of increasing major CV events was identified. Copyright Â
© 2010 Société française de rhumatologie. Published by Elsevier SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20471897     DOI: 10.1016/j.jbspin.2010.02.040

Source DB:  PubMed          Journal:  Joint Bone Spine        ISSN: 1297-319X            Impact factor:   4.929


  26 in total

1.  Management of cardiovascular risk in patients with rheumatoid arthritis: evidence and expert opinion.

Authors:  Inge A M van den Oever; Alper M van Sijl; Michael T Nurmohamed
Journal:  Ther Adv Musculoskelet Dis       Date:  2013-08       Impact factor: 5.346

2.  Glucocorticoids improve endothelial function in rheumatoid arthritis: a study in rats with adjuvant-induced arthritis.

Authors:  F Verhoeven; P Totoson; K Maguin-Gaté; A Prigent-Tessier; C Marie; D Wendling; J Moretto; C Prati; C Demougeot
Journal:  Clin Exp Immunol       Date:  2017-03-09       Impact factor: 4.330

3.  NT-proBNP levels may be influenced by inflammation in active ankylosing spondylitis receiving TNF blockers: a pilot study.

Authors:  Julio C B Moraes; Ana C M Ribeiro; Carla G S Saad; Alessandro C Lianza; Clovis A Silva; Eloísa Bonfá
Journal:  Clin Rheumatol       Date:  2013-02-05       Impact factor: 2.980

4.  The major determinants of arterial stiffness in Korean patients with rheumatoid arthritis are age and systolic blood pressure, not disease-related factors.

Authors:  Young-Sam Kim; Yoon-Kyoung Sung; Chan-Bum Choi; Wan-Sik Uhm; Tae-Hwan Kim; Jin-Ho Shin; Jae-Bum Jun
Journal:  Rheumatol Int       Date:  2011-11-06       Impact factor: 2.631

5.  Assessment of hemostatic disturbances in women with established rheumatoid arthritis.

Authors:  Aleksandra Vranic; Iva Pruner; Mirjana Veselinovic; Nida Soutari; Anica Petkovic; Vladimir Jakovljevic; Aleksandra Antovic
Journal:  Clin Rheumatol       Date:  2019-06-17       Impact factor: 2.980

6.  Non-ST-Segment Elevation Myocardial Infarction Shortly After Starting Steroid Replacement Therapy in a Patient With Adrenal Insufficiency.

Authors:  Mustafa Ahmed; Abdul Majeed Maliyakkal
Journal:  Cureus       Date:  2022-05-16

Review 7.  Rheumatoid arthritis and cardiovascular disease: an update on treatment issues.

Authors:  Medha Barbhaiya; Daniel H Solomon
Journal:  Curr Opin Rheumatol       Date:  2013-05       Impact factor: 5.006

Review 8.  Endothelial dysfunction in inflammatory bowel diseases: Pathogenesis, assessment and implications.

Authors:  Dorota Cibor; Renata Domagala-Rodacka; Tomasz Rodacki; Artur Jurczyszyn; Tomasz Mach; Danuta Owczarek
Journal:  World J Gastroenterol       Date:  2016-01-21       Impact factor: 5.742

9.  Atherosclerosis and rheumatoid arthritis: more than a simple association.

Authors:  Lorenzo Cavagna; Nicola Boffini; Giovanni Cagnotto; Flora Inverardi; Vittorio Grosso; Roberto Caporali
Journal:  Mediators Inflamm       Date:  2012-09-13       Impact factor: 4.711

Review 10.  Cardiovascular Disease in Rheumatoid Arthritis: Risk Factors, Autoantibodies, and the Effect of Antirheumatic Therapies.

Authors:  Mir Sohail Fazeli; Vadim Khaychuk; Keith Wittstock; Boris Breznen; Grace Crocket; Mir-Masoud Pourrahmat; Leticia Ferri
Journal:  Clin Med Insights Arthritis Musculoskelet Disord       Date:  2021-06-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.